NovaBridge Biosciences (NBP)
NASDAQ:NBP
Want to see NBP full AI Analyst Report?
Top Page
NovaBridge Biosciences
(NASDAQ:NBP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▼(-7.41% Downside)
Action:ReiteratedDate:04/12/26
The score is pressured primarily by weak financial performance (persistent losses, minimal recent revenue, and ongoing cash burn). Technicals add downside bias with a clear downtrend across key moving averages and negative MACD. Valuation is also constrained because the company is loss-making (negative P/E) and offers no dividend yield support.
Positive Factors
Cash Runway / Liquidity
A substantial year-end cash balance provides multi-year runway to fund mid-stage trials and platform development, materially reducing near-term financing risk. This enables NovaBridge to advance givastomig and VIS-101 through registrational-enabling studies and preserves optionality for partnering or out-licensing.
Negative Factors
Persistent Cash Burn
Multi-year negative operating and free cash flows indicate structural cash burn that can erode flexibility if clinical timelines slip or costs rise. Even with current cash, sustained negative cash generation raises dependency on financing or partnerships to complete pivotal trials and commercialize assets.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Runway / Liquidity
A substantial year-end cash balance provides multi-year runway to fund mid-stage trials and platform development, materially reducing near-term financing risk. This enables NovaBridge to advance givastomig and VIS-101 through registrational-enabling studies and preserves optionality for partnering or out-licensing.
Read all positive factors
NovaBridge Biosciences (NBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$271.15M
Dividend YieldN/A
Average Volume (3M)925.28K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding115,381,690
10 Day Avg. Volume859,716
30 Day Avg. Volume925,284
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)11.54
Price to Sales (P/S)0.00
P/FCF Ratio-129.35
Enterprise Value/Market Cap6.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.08K
Enterprise Value/Ebitda-11.15
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
NovaBridge Biosciences Business Overview & Revenue Model
Company Description
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for ...
NovaBridge Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 4.49M | -10.70M | 88.03M |
| Gross Profit | -6.00M | 0.00 | 4.49M | -248.80M | 41.59M |
| EBITDA | -93.41M | -373.45M | -344.25M | -51.23M | -2.06B |
| Net Income | -46.27M | -162.26M | -1.47B | -2.51B | -2.33B |
Balance Sheet | |||||
| Total Assets | 260.52M | 212.68M | 2.61B | 4.07B | 5.63B |
| Cash, Cash Equivalents and Short-Term Investments | 210.84M | 173.40M | 2.29B | 3.45B | 670.96M |
| Total Debt | 3.07M | 3.88M | 133.87M | 38.29M | 112.45M |
| Total Liabilities | 29.58M | 11.52M | 894.81M | 1.07B | 1.04B |
| Stockholders Equity | 230.94M | 201.16M | 1.72B | 3.01B | 4.59B |
Cash Flow | |||||
| Free Cash Flow | -20.60M | -52.72M | -73.02M | -1.15B | -1.00B |
| Operating Cash Flow | -20.60M | -52.67M | -72.85M | -1.10B | -973.09M |
| Investing Cash Flow | 104.97M | -135.97M | -107.63M | 458.38M | -727.21M |
| Financing Cash Flow | 57.73M | -334.89K | -8.25M | 42.36M | 593.92M |
NovaBridge Biosciences Technical Analysis
2.70
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBP, the sentiment is undefined. The current price of 2.7 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for NBP.
NovaBridge Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
NovaBridge Biosciences Corporate Events
NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs
Apr 7, 2026
On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring a strategic shift into a global biotech platform built around two mid-stage, potentially class-leading programs, givastomig for gastric cancer and VIS-101 f...
NovaBridge Wins FDA Backing for Accelerated Approval Pathway for Givastomig in Gastric Cancer
Mar 16, 2026
On March 16, 2026, NovaBridge Biosciences reported that a recent U.S. Food and Drug Administration Type B meeting confirmed the potential eligibility of its lead oncology asset, givastomig, for an accelerated approval pathway in first-line Her2-ne...
NovaBridge and Visara Post Strong VIS-101 Phase 2a Wet AMD Data, Plot Path to Late-Stage Trials
Mar 9, 2026
On March 9, 2026, NovaBridge Biosciences and its subsidiary Visara reported positive topline Phase 2a results for VIS-101 in wet age-related macular degeneration, with both 3 mg and 6 mg cohorts showing mean best-corrected visual acuity gains of m...
NovaBridge Biosciences Sets March 9 Call to Review Phase 2a VIS-101 Data in Wet AMD
Mar 3, 2026
NovaBridge Biosciences, a Nasdaq-listed global biotechnology platform company, develops oncology and ophthalmology assets including givastomig, a Claudin 18.2 x 4-1BB bispecific antibody in Phase 2 for gastric and other gastrointestinal cancers, a...
NovaBridge Biosciences Unveils February Investor Deck Detailing Global Hub-and-Spoke Biotech Strategy
Feb 25, 2026
On February 6, 2026, NovaBridge Biosciences issued an investor presentation outlining its transition toward a global “Biotechnology Platform 3.0,” emphasizing a hub-and-spoke business that connects Asian-origin innovations with interna...
NovaBridge Biosciences Names Emmett Cunningham Vice Chairman to Bolster Biotech Platform
Feb 19, 2026
On February 17, 2026, NovaBridge Biosciences appointed Emmett T. Cunningham Jr., MD, PhD, MPH, as Vice Chairman of its board of directors and a member of its Research and Development Committee, effective immediately. The move brings more than two ...
NovaBridge Doses First Patient in Global Phase 2 Gastric Cancer Trial of Givastomig
Feb 17, 2026
On February 17, 2026, NovaBridge Biosciences announced it has dosed the first patient in a global, randomized Phase 2 study of givastomig in combination with nivolumab and mFOLFOX6 for first-line HER2-negative metastatic gastric cancer. The trial,...
NovaBridge Biosciences Unveils February 2026 Investor Presentation Highlighting Global Hub-and-Spoke Biotech Strategy
Feb 6, 2026
On February 6, 2026, NovaBridge Biosciences furnished an updated investor presentation outlining its evolution into a global ‘hub-and-spoke’ platform designed to accelerate the development and internationalization of Asian-origin biolo...
NovaBridge CEO Begins Open-Market Purchases of Company ADSs
Jan 22, 2026
On January 22, 2026, NovaBridge Biosciences disclosed that its chief executive officer and board member, Dr. Sean (Xi‑Yong) Fu, has begun purchasing the company’s American depositary shares in the open market, with an intention to inve...
NovaBridge Biosciences Executive Begins Open-Market ADS Purchases
Jan 22, 2026
On January 21, 2026, NovaBridge Biosciences announced that its Chief Business Development Officer and board member, Dr. Sean Cao, has begun purchasing the company’s American depositary shares in the open market, with plans to buy up to $100,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.